Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.

JAMA · March 2012 · S Matthijs Boekholdt, Benoit J Arsenault, Samia Mora, Terje R Pedersen, John C LaRosa, et al.

What this study found

Among statin-treated patients, on-treatment levels of LDL-C, non-HDL-C, and apoB were each associated with risk of future major cardiovascular events, but the strength of this association was greater for non-HDL-C than for LDL-C and apoB.

Open on PubMed DOI

Landmark studysystematic_review

Why this trial matters

LDL cholesterol cardiovascular meta-analysis

How RAGMD uses this study

Clinical questions this paper informs

Synthesis lives on the evidence question — this page shows where the study sits in that analysis.

Supporting literature

Is ApoB more useful than LDL-C for cardiovascular risk prediction?

Prospective cohorts and meta-analyses suggest ApoB may capture atherogenic particle burden better than LDL-C alone, particularly when triglycerides are elevated or LDL particles are discordant with LDL-C.

Open evidence analysis

Read the evidence analysis Research library